Philadelphia Chromosome-Positive De Novo Acute Myeloid Leukemia Treated With Chemotherapy and Second-Generation Tyrosine Kinase Inhibitor

Cureus
doi 10.7759/cureus.5135
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cureus, Inc.

Related search

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Thyroid
MedicineEndocrinologyMetabolismDiabetes
2010English

De Novo Philadelphia Positive Acute Myeloid Leukemia With Extensive Basophilia: A Diagnostic Dilemma

Indian Journal of Hematology and Blood Transfusion
Hematology
2016English

Correlation Between Deletion of the CDKN2 Gene and Tyrosine Kinase Inhibitor Resistance in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2016English

Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2011English

Philadelphia Chromosome-Positive Acute Myelocytic Leukemia With French-American-British M2 Morphology, Refractory to Tyrosine Kinase Inhibitors

Tenri Medical Bulletin
2012English

Philadelphia Chromosome‐negative Acute Leukemia in Chronic Myeloid Leukemia

American Journal of Hematology
Hematology
2019English

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Expressing P190BCR-Abl.

Internal Medicine
Internal MedicineMedicine
2002English

Upfront Treatment With the First and Second-Generation Tyrosine Kinase Inhibitors in Ph-Positive Acute Lymphoblastic Leukemia

Oncotarget
Oncology
2017English

Tyrosine Kinase Inhibition in Acute Myeloid Leukemia

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy